Coherus Oncology, Inc. current report, 07 June 2023

Full document

Business Context and Reporting Period

This Form 8-K reports on the 2023 Annual Meeting of Stockholders held by Coherus BioSciences, Inc. on June 7, 2023. The meeting was conducted virtually via the Internet. As of the record date on April 10, 2023, there were 80,542,826 shares of common stock outstanding.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.

Material Changes and Voting Results

A total of 65,906,316 shares were voted on three proposals:

  • Proposal 1 (Election of Directors): Stockholders elected Class III nominees Dennis M. Lanfear and Mats L. Wahlström to the Board.
    • Dennis M. Lanfear: 57,378,374 votes FOR; 1,424,977 votes WITHHELD.
    • Mats L. Wahlström: 42,646,152 votes FOR; 16,157,199 votes WITHHELD.
  • Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
    • 65,375,866 votes FOR; 434,987 votes AGAINST; 95,463 votes ABSTAIN.
  • Proposal 3 (Say-on-Pay): Stockholders approved the non-binding advisory resolution regarding executive compensation.
    • 55,379,513 votes FOR; 3,233,870 votes AGAINST; 189,968 votes ABSTAIN.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.

Key Facts for Investor Verification

  • Verify the tenure of newly elected directors Dennis M. Lanfear and Mats L. Wahlström, who serve until the 2026 annual meeting.
  • Confirm the significant number of withheld votes for Mats L. Wahlström (16,157,199) compared to Dennis M. Lanfear (1,424,977).
  • Note that the "Say-on-Pay" proposal received approximately 84.5% support (55.4M FOR vs. 3.2M AGAINST).
  • Review the Definitive Proxy Statement on Schedule 14A filed on April 17, 2023, for detailed background on the proposals.